GTx Inc., of Memphis, Tenn., reported data from a Phase IIb study showing that enobosarm, a selective androgen-receptor modulator, may play a role in the management of cancer patients with muscle wasting by improving physical function. Of the 159 subjects randomized to the study, 103 had physical function assessed at both baseline and following 16 weeks of treatment.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST